<?xml version="1.0" encoding="UTF-8"?><feed xmlns="http://www.w3.org/2005/Atom">
  <title>汉靓的医药科技前沿 | wechat-feeds</title>
  <id>https://github.com/hellodword/wechat-feeds</id>
  <updated>2020-10-29T23:19:01+08:00</updated>
  <subtitle>专注于生物医药领域，分享最前沿的技术，最领先的商业模式，最新的政策，以及对生物医药行业发展的所思所想</subtitle>
  <link href="https://github.com/hellodword/wechat-feeds"></link>
  <author>
    <name>hellodword</name>
  </author>
  <entry>
    <title>【83】荣昌生物招股书解读之二：从RC48谈Her2靶向抗体偶联药物（ADC）</title>
    <updated>2020-09-20T15:18:19+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-09-20:/s/BY_NQResEqliSwltlPFWtw</id>
    <link href="https://mp.weixin.qq.com/s/BY_NQResEqliSwltlPFWtw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【82】荣昌生物招股书解读之一：从泰它西普（Telitacicept）谈系统性红斑狼疮新药进展</title>
    <updated>2020-08-30T13:50:30+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-08-30:/s/af5b_6hjlTwDlylM84tX-A</id>
    <link href="https://mp.weixin.qq.com/s/af5b_6hjlTwDlylM84tX-A" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【81】从Illumina、Guardant、燃石和泛生子的二季报谈NGS行业的最新动态</title>
    <updated>2020-08-16T20:26:18+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-08-16:/s/Xm9_kddnmoLk_1OyYuUoMw</id>
    <link href="https://mp.weixin.qq.com/s/Xm9_kddnmoLk_1OyYuUoMw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【80】再谈BCL-2：从亚盛的BCL-2抑制剂和阿斯利康BTK的合作谈起</title>
    <updated>2020-08-01T18:20:58+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-08-01:/s/Rtn_Ljw8ioHa2gM0vSr-Tw</id>
    <link href="https://mp.weixin.qq.com/s/Rtn_Ljw8ioHa2gM0vSr-Tw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【79】再谈CDK4/6: 从嘉和生物的招股书说起</title>
    <updated>2020-07-19T09:53:11+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-07-19:/s/F3pSMaEIVeO6q2DNl_uRJg</id>
    <link href="https://mp.weixin.qq.com/s/F3pSMaEIVeO6q2DNl_uRJg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【78】CD47系列报告之二：Trillium、ALX和宜明昂科的Fc融合蛋白</title>
    <updated>2020-07-05T12:37:38+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-07-05:/s/H_wnZTy07Dt3ofBpKju-zg</id>
    <link href="https://mp.weixin.qq.com/s/H_wnZTy07Dt3ofBpKju-zg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【77】燃石医学的招股书解读&amp;个人思考（内含和Guardant的比较）</title>
    <updated>2020-06-21T11:53:18+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-06-21:/s/3Lq-EaFFIvx627K-qX2v3A</id>
    <link href="https://mp.weixin.qq.com/s/3Lq-EaFFIvx627K-qX2v3A" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【76】读书笔记之《坏血》：硅谷明星血检公司Theranos的崛起和陨落</title>
    <updated>2020-06-14T12:24:30+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-06-14:/s/YQqJann_a207CeWUYlivOQ</id>
    <link href="https://mp.weixin.qq.com/s/YQqJann_a207CeWUYlivOQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【75】CD47系列报告之一：从49亿美金被Gilead收购的Forty Seven说起</title>
    <updated>2020-06-07T00:22:25+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-06-07:/s/Z1pcKyYWA-CAUXKBhf16vA</id>
    <link href="https://mp.weixin.qq.com/s/Z1pcKyYWA-CAUXKBhf16vA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【74】一张图展示Illumina的2020Q1业绩&amp;NGS如何抗击COVID-19</title>
    <updated>2020-05-31T15:26:11+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-05-31:/s/4TPgDAqd35PbannYgsgBWg</id>
    <link href="https://mp.weixin.qq.com/s/4TPgDAqd35PbannYgsgBWg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
</feed>